BRAVO-LMNCT07789912
BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Phase 2 → Not applicable Show 6 more changesShow less
- Recruitment opened
- Eligibility criteria expanded, about 14 words
- Start date changed from estimate of Oct 1, 2026 to Oct 13, 2026
- Primary and study completion dates: Oct 1, 2030 to Oct 13, 2030
- Secondary endpoints: details revised at 8 of 12 entries
- Site details revised
- Minor Secondary endpoints: 7 to 12v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Participants in this group will undergo radiation treatments using brain-avoidant proton craniospinal irradiation (CSI). The prescribed radiation dose for all participants will be 30Gy (Cobalt Gray Equivalent \[CGE\]) in 10 fractions.
Participants who decline BRAVO-pCSI will have the option to enroll in a non-interventional exploratory arm. Participants in this group will undergo the same baseline and follow-up assessments as participants receiving BRAVO-pCSI, including radiographic evaluations, cerebrospinal fluid (CSF) and serum assessments, neurocognitive testing, and quality-of-life assessments. No study intervention will be administered.
Radiation: Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI)
Sites
1 site in 1 country
- University of MiamiMiami, Florida, United States